My wife is also a Duke patient and is currently on the rotational chemo regimen. She has had surgery (100% resection, IL13 trial for newly-diagnosed, radiation, and is in the middle of her third round of Temodar (200mg/m^2). Temodar has been proven to be the most effective chemo drug available to treat GBM patients - yielding a 2.5 month increase in survival according to a European/Canadian study. However, Temodar is not a cure. Temodar works by interfering with DNA replication when cancer cells divide - targeting 3 separate chemical locations. A certain percentage of cancer cells are able to repair the damage done by Temodar and continue dividing. Eventually, the cells susceptible to Temodar will be killed and the ones resistant will become predominant, leading to tumor recurrence and progression. Hence the logic behind a rotation. The major centers (Duke among them) are ahead of the ballgame in treating patients as individuals rather than a group. Our local Oncologist in Atlanta wanted my wife on "Temodar until Progression", which didn't work for us. Since BCNU and CCNU are chemical cousins of Temodar, you begin to have fewer options once Temodar no longer works (and only 30%-40% of patients respond to Temodar anyway...). My wife fits the profile for Tarceva (EGFRvIII expression, PTEN intact) and that will be the next drug in her rotation. We are looking at combinging Temodar and Tarceva for 12 weeks, then rotating to CPT-11/Avastin (CPT-11 inhibits Topoisomerase I and has a completely different kill mechanism than Temodar, while Avastin is an Angiogenesis inhibitor) for another 12, then finishing our 52 weeks with more Temodar. I don't know if that helps or not. Think of GBM's as an enemy camped out in your father's brain. Once you kill as much as you can with surgery and radiation, you have to block ALL of the roads leading out of the camp to keep the cancer in check. If you block only one, eventually the enemy will find a way out of camp and show up on your flanks. Best of luck with you and your father.